Home
| Site map | Contact
us
Change type size: A
| A
The team
Management team
Dr Crawford Brown Chief
Executive Officer
crawford.brown@edenbiodesign.com
Crawford co–founded Eden Biodesign in 2000 from Celltech–Medeva where he was Director of Product Development responsible for developing and manufacturing the biotech product pipeline. Among his achievements Crawford managed and led a successful pan–European submission for a complex recombinant vaccine which included an EMEA sponsored pre–approval inspection. Crawford has held senior technical management positions in both biotech and pharmaceutical companies and has been actively engaged in commercial biopharmaceutical development for over 20 years.
As well as leading the company, he retains a major role in Eden Biodesign’s consultancy services.
Dr
Anita Bate Chief
Scientific Officer
anita.bate@edenbiodesign.com
Anita’s overall role is to ensure Eden Biodesign maintains its position as leader in the technical skill sets of product development.
Anita herself has a very broad skill base having held senior positions in the pharmaceutical industry managing both analytical and process development groups. She has worked on over 40 wide ranging client projects for Eden Biodesign as a consultant and is particularly expert in development genetics, due diligence for in licensing, viral testing and regulatory affairs.
Mrs
Janice Stewart Finance
Director
janice.stewart@edenbiodesign.com
Janice qualified as a chartered accountant in 1987 and worked in practice, specialising in audit and tax, before moving into the Biotech industry in 1993. Since then, she has gained financial and business experience across a variety of industries.
Prior to joining Eden Biodesign, Janice headed up the European finance function of ACL AB, a successful transatlantic shipping company with offices located across Europe. She took a senior role in helping to restructure the group prior to and following its purchase by the Grimaldi Group. Her main responsibilities at Eden Biodesign are to control and direct the Group’s contractual, financial and taxation affairs.
Mrs
Alison Justice Quality
Assurance Director
alison.justice@edenbiodesign.com
Alison’s role is to ensure Eden Biodesign’s systems and procedures are compliant with the cGMP requirements applicable for the design, development and delivery of clinical trials materials.
Alison has held a variety of QC/QA roles within pharmaceutical, fine chemical and medical device contract manufacturing organisations. Alison is an experienced Quality System auditor familiar with quality management system requirements for Pharmaceutical, Medical Device and Active Pharmaceutical Ingredients manufacture.
Prior to joining Eden Biodesign, Alison was Quality Manager at an AIM listed woundcare company where she successfully implemented ISO13485:2003 and provided support to several successful FDA submissions.
Dr
Derek Ellison Chief
Operating Officer
derek.ellison@edenbiodesign.com
Derek is responsible for the operational activities of Eden Biodesign, including Development, cGMP production, QC, client project management and maintaining Eden's state of the art facilities. Previously, Derek has led Eden Biodesign' s commercial activities with responsibility for managing global business development. Derek has extensive expertise in product development, having provided specialist analytical, technical transfer and regulatory consultancy and training to over 30 clients on behalf of Eden Biodesign.
Prior to this, Derek led the Protein Analytical Development Team at Celltech–Medeva and played a key role in the successful market approval of the company’s lead recombinant vaccine product. Before working in the biopharm industry and co–founding Eden Biodesign, Derek was a Post–Doctoral Researcher funded by the British Heart Foundation.
Dr Roger Lias President,
Eden Biodesign, Inc. & Group Commercial Director
roger.lias@edenbiodesign.com
Roger’s responsibilities
include identifying and establishing strategic business partnerships and
expanding Eden Biodesign's offer to the large North American biopharmaceutical
sector. In addition, Roger is responsible for Global Business Development
and managing Eden’s continued strong growth in Europe and Asian
markets.
Roger has extensive experience in the biotechnology industry with a specific
emphasis on biomanufacturing services. Prior to joining Eden, Roger held
the position of Vice President, Sales and Business Development at Cytovance
Biologics. At KBI BioPharma, a start-up contract biomanufacturing company,
he played an active role in securing funding, building revenues and was
responsible for identifying and establishing strategic business partnerships
and new business relationships. Prior to this, he was Vice President,
Business Development at Diosynth where he had global responsibility and
headed North American sales and marketing for Lonza Biologics. In both
cases Roger was instrumental in generating substantial revenue growth.
Mr
Simon Routledge Engineering
& Validation Director
simon.routledge@edenbiodesign.com
Simon has over 15 years experience in the industry including experience in Quality Control and Upstream Process Development and as the Production Manager for early and late phase biopharmaceuticals at Celltech-Medeva. Under Simon's management the company successfully validated the pilot facilities, which subsequently passed pre-approval inspection for provision of marketed product.
Simon then joined Eden Biopharm consultancy, where he supported clients with advice and practical support for quality, compliance and validation issues with subsequent full time consultancy support for the design and qualification of the NBC cGMP facility and systems. Simon's responsibilities at Eden Biodesign include managing the maintenance and upkeep of the NBC with particular regard to the engineering operations and the validation of equipment and systems in line with Eden 's Quality and HSE Policies and Procedures.
